Dermatoses in overweight and obese children and their relationship with insulin and skin color

• Published in: Journal of cosmetic dermatology 2023-10, Vol.22 (10), p.2791-2798
• Main Authors: Kus, Mine Mujde, Mulayim, Mehmet Kamil, Kus, Celal, Doganer, Adem, Ozturk, Perihan, Temiz, Fatih, Nazik, Hulya
• Format: Article
• Language: English
• Subjects: Acne; Bacterial infections; Insulin resistance; Obesity; Viral infections
• ISSN: 1473-2130; 1473-2165
• DOI: 10.1111/jocd.15773

The aim of the present study was to investigate the prevalence of obesity-related dermatoses in obese children, and the association between these dermatoses and insulin resistance as well as skin color. Obese, overweight, and normal weight children according to body mass index who were followed up and treated in the outpatient clinics were included in the study. Dermatological examinations of the participants were performed, and fasting insulin and glucose levels were checked. The obese and overweight children were evaluated as the patient group (70 girls, 41 boys, mean age: 12.37 ± 3.14 years). One hundred one healthy children with normal weight were determined as the control group (59 girls, 42 boys, mean age: 12.15 ± 2.43). The first five common dermatoses in the patient group when compared with the control group were keratosis pilaris (KP), striae distensae, hyperhidrosis, acanthosis nigricans (AN), and plantar hyperkeratosis. The first five dermatoses which were positively correlated with formation and insulin resistance were KP, striae distensae, AN, hyperhidrosis, and plantar hyperkeratosis. According to the Fitzpatrick skin scale, we found that the darker the skin color, the higher the probability of AN and KP (OR, 0.298; 95% CI, 0.106-0.834, p = 0.021; OR, 0.306; 95% CI, 0.117-0.796, p = 0.015, respectively). Some dermatoses associated with obesity and insulin resistance were not found in obese children, or there was no significant association. These results indicate that many skin morbidities may be prevented by preventing and treating obesity and insulin resistance in the early period.